Clinical trial · Observational
Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression
Prospective Cohort Study for Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
DLBCL has the highest frequency out of all lymphoid malignancies. With the recent development of antitumor agents targeting intracellular/extracellular cell signaling pathways, patients have access to various treatment options after relapse. Therefore, for the purpose of developing effective treatment strategies, large-scale genomic data accumulation is necessary to understand the mechanism of relapse and refractory state of DLBCL.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Large B-Cell, Diffuse | Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Next generation sequencing with tumor tissue
- timeFrame
- 2-year follow-up from the end of the enrollment
- description
- To understand the mechanism of relapse, targeted sequencing based on HemaScan panel including the essential genes (including 425 whole exome).
- measure
- Next generation sequencing with blood
- timeFrame
- 2-year follow-up from the end of the enrollment
- description
- To understand the mechanism of relapse, targeted sequencing based on HemaScan panel including the essential genes (including 425 whole exome).
Secondary outcomes (2)
- measure
- Data which included salvage chemotherapy.
- timeFrame
- 2-year follow-up from the end of the enrollment
- description
- Progression free survival, response rate for salvage chemotherapy.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histopathologically confirmed DLBCL * DLBCL who relapsed or were refractory to first-line treatment with rituximab-based immunotherapy * Available for genomic analysis of tissues both at diagnosis (paraffin-embedded and stored) and at relapse (paraffin-embedded) * Aged ≥18 years * Written informed consent for participation in the prospective cohort study * Written informed consent to peripheral blood collection and genetic testing of human tissues Exclusion Criteria: * No lymphoid malignancy, e.g. myeloid leukemia * Any of the following lymphoid malignancies: 1. Plasma cell dyscrasia, amyloidosis 2. Hodgkin lymphoma 3. Subtypes of B cell non-Hodgkin lymphoma, other than DLBCL 4. T or NK(Natural Killer) cell non-Hodgkin lymphoma 5. Other diseases in the WHO(World Health Organization) classification of lymphoid malignancies * Experienced a relapse before * Insufficient or no tissue sample at diagnosis for genomic analysis * Can not understand or provide written informed consent * Who do not provide written informed consent to blood collection and genetic testing
References
Publications (0)
Data not yet available